Viyash Scientific Ltd. Seeks Shareholder Approval for Key Appointments via Postal Ballot
Viyash Scientific is seeking shareholder approval via postal ballot for key appointments and stock options. This includes appointing Dr. Haribabu Bodepudi as MD & Group CEO and Mr. Srinivas Vasireddy as Whole-time Director (Executive) for two years. Mr. Rajaram Narayanan will be appointed Whole-time Director and CEO – Animal Health Business. E-voting runs from Feb 11 to Mar 12, 2026.
The appointment of key management personnel and the grant of stock options are significant events that can influence the company's future strategy and performance, thus having a medium impact.
The announcement is a procedural disclosure regarding shareholder voting on appointments and stock options. It does not contain information that would immediately suggest a positive or negative financial impact.
Viyash Scientific Limited has issued a Postal Ballot Notice dated February 10, 2026, seeking shareholder approval for several crucial matters through remote e-voting. The key agenda items include the appointment and remuneration of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term, and the grant of stock options exceeding 1% of the issued capital to an identified employee.
Additionally, the company seeks approval for the appointment of Mr. Rajaram Narayanan as Whole-time Director and CEO – Animal Health Business, and Mr. Srinivas Vasireddy as Whole-time Director (Executive) for a two-year period. The remote e-voting process will commence on Wednesday, February 11, 2026, at 9:00 AM IST and conclude on Thursday, March 12, 2026, at 5:00 PM IST. The results are expected to be declared on or before Monday, March 16, 2026. The company has engaged NSDL for the remote e-voting facility.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.